01/15/2012 - Eppendorf acquires DASGIP Group
Eppendorf AG today announced its acquisition of the DASGIP Group, a technology leader in the fields of bioprocess and information technology. DASGIP, with offices in Juelich, Germany, and Shrewsbury, Massachusetts, has established a high reputation as developer and manufacturer of parallel bioreactor systems andinnovative control and analysis software.
Eppendorf CEO Dirk Ehlers, Ph.D., commented the transaction: "DASGIP is a strategically important addition to the Eppendorf Group. DASGIP’s high quality parallel bioreactors and software solutions nicely complement the current offering of our New Brunswick product lines. They allow us to forge a comprehensive suite of products for bioprocess research applications, development and scale up, from 30 mL to 3,000 liters. Furthermore, the advanced software concepts will position DASGIP as a strong Competence Center in these fields.”
DASGIP CEO Thomas Drescher, Ph.D., added: “The DASGIP and Eppendorf strategies and corporate cultures have an excellent fit. We look forward to combining our technical expertise with the broad range of Eppendorf lab solutions in the fields of liquid-, sample- and cell handling. DASGIP products now can be brought to allmajor markets worldwide with the additional sales and service force available through the regional Eppendorf organizations.”
The deal closed on January 2, 2012. Financial terms were not disclosed.